Hepatitis C Virus Testing and Care Cascade Among Transgender and Gender Diverse Individuals.

Am J Prev Med

Department of Health Behavior & Health Education, School of Public Health, University of Michigan, Ann Arbor, Michigan; Institute for Social Research, University of Michigan, Ann Arbor, Michigan.

Published: May 2023

Introduction: Hepatitis C virus (HCV) prevalence among transgender and gender-diverse individuals ranges from 1.8% to 15.7% versus 1% in the general population. Previous HCV studies inclusive of transgender and gender-diverse individuals primarily rely on convenience-based sampling methods or are geographically restricted. The purpose of this study is to compare the prevalence of HCV diagnoses, testing, and care engagement between transgender and gender-diverse and cisgender individuals.

Methods: Using Optum's de-identified Clinformatics® Data Mart Database, in 2022, the unadjusted prevalence of HCV testing among all adults and people who inject drugs from January 2001 to December 2019 was measured. Multivariable logistic regression was used to compare the adjusted odds of HCV diagnoses and care engagement by gender subgroup.

Results: The overall unadjusted frequency of HCV diagnoses among transgender and gender-diverse individuals was approximately 3 times that of cisgender individuals (1.06% vs 0.38%, p<0.001), including among people who inject drugs (6.36% vs 2.36%, p=0.007). Compared with cisgender women, transfeminine/nonbinary individuals had over 5 times the adjusted odds of a HCV diagnosis and approximately 3.5 times the odds of being tested for HCV. In addition, compared with cisgender women, transfeminine/nonbinary individuals had significantly increased odds of having a HCV‒related procedure (e.g., abdominal ultrasounds, liver biopsies, Fibroscans). Cisgender men had significantly increased odds of receiving HCV medication compared with cisgender women.

Conclusions: Although testing was higher among transgender and gender-diverse individuals, the higher overall frequency of HCV diagnoses among transgender and gender-diverse than among cisgender individuals signals persistent health disparities. Interventions are warranted to prevent HCV and increase ongoing testing and treatment uptake among transgender and gender-diverse populations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121731PMC
http://dx.doi.org/10.1016/j.amepre.2023.01.005DOI Listing

Publication Analysis

Top Keywords

transgender gender-diverse
16
gender-diverse individuals
12
hcv diagnoses
12
hepatitis virus
8
testing care
8
prevalence hcv
8
care engagement
8
hcv
6
transgender
5
individuals
5

Similar Publications

Associations of Faith Community Rejection with Social Support and Health Outcomes among LGBTQ+ Older Adults.

J Gerontol B Psychol Sci Soc Sci

January 2025

Department of Medicine, Health, and Society, Vanderbilt University, Nashville, Tennessee, USA.

Objectives: Lesbian, gay, bisexual, transgender, and queer (LGBTQ+) older adults have varied experiences with faith communities, ranging from affirmation to religious trauma. We investigate how faith community rejection impacts social support and health outcomes among LGBTQ+ older adults in the Southern United States.

Methods: We analyze Wave 1 data from the LGBTQ+ Social Networks, Aging, and Policy Study (QSNAPS), collected between April 2020 and September 2021.

View Article and Find Full Text PDF

Transgender and gender diverse (TGD) individuals face significant barriers to healthcare, necessitating the development of TGD-friendly medical services. In India, healthcare systems have only recently begun addressing the unique needs of TGD individuals, particularly with the advent of the Transgender Persons Act 2019. This article outlines the establishment of a comprehensive TGD clinic within a multidisciplinary framework.

View Article and Find Full Text PDF

Background: Transgender and gender diverse (TGD) people seek gender-affirming care at any age to manage gender identities or expressions that differ from their birth gender. Gender-affirming hormone treatment (GAHT) and gender-affirming surgery may alter reproductive function and/or anatomy, limiting future reproductive options to varying degrees, if individuals desire to either give birth or become a biological parent.

Objective And Rationale: TGD people increasingly pursue help for their reproductive questions, including fertility, fertility preservation, active desire for children, and future options.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!